Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor–Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy

已完结 20 由 yantai yang kong 发布于 2025/8/3 13:30:59

DOI:10.1001/jamaoncol.2025.2092
作者：Zhonghua Tao, Jian Zhang, Qiufan Zheng, Yongsheng Wang, Li Cai, Hongyan Xu, Xinhua Xu, Xiangshun Kong, Sijuan Ding, Chunfang Hao, Hao Wang, Hong Zong, Xin Jin, Xinshuai Wang, Yang Li, Xiuli Yang, Weij
文献类型：期刊论文
补充材料：只需要正文

JAMA

Abstract：ImportanceCyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy (ET) are now considered the standard treatment regimen for hormone receptor–positive (HR+) and ERBB2 (f

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Mixed-Dimensional PtSe2/Bi2Te3/Pyramid Si Heterojunction with a Light-Trapping Structure for Highly Sensitive Ultrabroadband Photodetection